Business Wire November 30, 2021
GE

Collaborations with SOPHiA GENETICS, The University of Cambridge and Optellum are intended expand access to the latest and most advanced technologies for cancer care

CHICAGO–(BUSINESS WIRE)–GE Healthcare announced collaborations with SOPHiA GENETICS, The University of Cambridge and Optellum as part of its vision to advance care, make precision health more accessible, and ultimately improve outcomes for cancer patients.

“Cross-functional partnerships between organizations are key to the creation of new approaches and intelligent tools that enable cancer to be detected as early as possible and with the greatest degree of accuracy”

Tweet this

These alliances are intended to help GE Healthcare support integrated health systems at the local level by providing the technology to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Precision Medicine, Provider
Related Articles:
Top 20 pharma companies by 2023 revenue
Regeneron launches $500m venture capital arm
STAT+: Pharmalittle: We’re reading about a J&J cough syrup, a Pfizer and Moderna patent suit, and more
Pharma Pulse 4/15/24: Human Oversight with AI in Clinical Research, The Health and Healthcare of Gen Xers
STAT+: Can investing in infectious disease pay off? Vir Biotechnology’s tightrope walk shows it’s a struggle

Share This Article